The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+ T cell-priming capacity of dendritic cells

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 169-177

  Platt, Andrew M ^a   Benson, Robert A ^a   Mcqueenie, Ross ^a   Butcher, John P ^a   Braddock, Martin ^b   Brewer, James M ^a   McInnes, Iain B ^a   Garside, Paul ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Autoimmunity; Dendritic cells; Rheumatoid arthritis; SYK kinase; T cells

Indexed keywords

CYTOKINE; DRUG METABOLITE; FC RECEPTOR; FOSTAMATINIB; GAMMA INTERFERON; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 17; PROTEIN KINASE SYK;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL LEVEL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FLUORESCENCE MICROSCOPY; IMMUNIZATION; IN VITRO STUDY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

EID: 84928738232     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu273     Document Type: Article

References (45)

1. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387-402.
2. Braselmann S, Taylor V, Zhao H et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complexmediated inflammation. J Pharmacol Exp Ther 2006; 319:998-1008.
3. Hilgendorf I, Eisele S, Remer I et al. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol 2011;31: 1991-9.
4. Colonna L, Catalano G, Chew C et al. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 2010; 185:1532-43.
5. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010;62:2086-92.
6. Bahjat FR, Pine PR, Reitsma A et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58:1433-44.
7. Matsubara S, Li G, Takeda K et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006; 173:56-63.
8. Pine PR, Chang B, Schoettler N et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007;124:244-57.
9. Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther 2008;10(Suppl 1):S1.
10. Duke O, Panayi GS, Janossy G, Poulter LW. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol 1982;49:22-30.
11. Seidl C, Donner H, Fischer B et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 1998;51:62-6.
12. Raychaudhuri S, Remmers EF, Lee AT et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008;40:1216-23.
13. Raychaudhuri S, Thomson BP, Remmers EF et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009;41: 1313-8.
14. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-15.
15. Luthra HS, McDuffie FC, Hunder GG, Samayoa EA. Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. Radioimmunoassay with monocylonal rheumatoid factor. J Clin Invest 1975;56:458-66.
16. Hay FC, Nineham LJ, Perumal R, Roitt IM. Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features. Ann Rheum Dis 1979;38:1-7.
17. Matsubara S, Koya T, Takeda K et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2006;34: 426-33.
18. Smith KM, Brewer JM, Rush CM, Riley J, Garside P. In vivo generated Th1 cells can migrate to B cell follicles to support B cell responses. J Immunol 2004;173:1640-6.
19. Lutz MB, Kukutsch N, Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
20. Regnault A, Lankar D, Lacabanne V et al. Fcγ receptormediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-80.
21. Tedder TF, Penta AC, Levine HB, Freedman AS. Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol 1990;144:532-40.
22. Celli S, Lemaitre F, Bousso P. Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity 2007;27:625-34.
23. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-9.
24. Rush CM, Millington OR, Hutchison S et al. Characterization of CD4+ T-cell-dendritic cell interactions during secondary antigen exposure in tolerance and priming. Immunology 2009;128:463-71.
25. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18.
26. Weinblatt ME, Kavanaugh A, Genovese MC et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.
27. AstraZeneca. AstraZeneca announces top-line results from phase III OSKIRA trials of fostamatinib and decision not to proceed with regulatory filingsPress release, 4 June 2013. http://www.astrazeneca.com/Media/ Press-releases/Article/20130504-astrazenecaannounces-topline-results-from-phase-iii-o (10 June 2014, date last accessed).
28. Rigel Pharmaceuticals. Rigel to focus on ITP, DLE and dry eye. Strategy provides multiple paths to phase 3/NDA in next 2-3 years. Press release, 5 September 2013. http://ir. rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle &ID=1852213&highlight (10 June 2014, date last accessed).
29. Sedlik C, Orbach D, Veron P et al. A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation. J Immunol 2003;170:846-52.
30. Nakashima K, Kokubo T, Shichijo M et al. A novel Syk kinase-selective inhibitor blocks antigen presentation of immune complexes in dendritic cells. Eur J Pharmacol 2004;505:223-8.
31. Benson RA, Patakas A, Conigliaro P et al. Identifying the cells breaching self-tolerance in autoimmunity. J Immunol 2010;184:6378-85.
32. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005;52:2307-12.
33. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
34. Laurent L, Clavel C, Lemaire O et al. Fcγ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011;70:1052-9.
35. Lebre MC, Jongbloed SL, Tas SW et al. Rheumatoid arthritis synovium contains two subsets of CD83-DCLAMP- dendritic cells with distinct cytokine profiles. Am J Pathol 2008;172:940-50.
36. Jongbloed SL, Lebre MC, Fraser AR et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther 2006;8:R15.
37. Fanger NA, Voigtlaender D, Liu C et al. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol 1997; 158:3090-8.
38. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
39. Tafuri A, Shahinian A, Bladt F et al. ICOS is essential for effective T-helper-cell responses. Nature 2001;409:105-9.
40. Akiba H, Takeda K, Kojima Y et al. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol 2005;175:2340-8.
41. Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001;98:39-45.
42. Murphy CA, Langrish CL, Chen Y et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198: 1951-7.
43. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118: 3537-45.
44. Hirota K, Hashimoto M, Yoshitomi H et al. T cell selfreactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007;204:41-7.
45. Koch AE, Kunkel SL, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.